Results 41 to 50 of about 1,428 (167)

Pharmacological research of a novel selective SGLT2 inhibitor, tofogliflozin

Pharmacological research of a novel selective SGLT2 inhibitor, tofogliflozin
学位の種別: 論文博士 審査委員会委員 : (主査)東京大学教授 九郎丸 正道, 東京大学教授 中山 裕之, 東京大学教授 久和 茂, 東京大学准教授 堀 正敏, 東京大学准教授 金井 ...
永田, 工
openaire   +2 more sources

Tofogliflozin

Reactions Weekly, 2017
openaire   +2 more sources

The Impact of Tofogliflozin on Physiological and Hormonal Function, Serum Electrolytes, and Cardiac Diastolic Function in Elderly Japanese Patients with Type 2 Diabetes Mellitus [PDF]

, 2022
The sodium glucose transporter 2 (SGLT2) inhibitor tofogliflozin is a glucose-lowering drug that causes the excretion of surplus glucose by inhibiting SGLT2.
Izumida, Toshihide, Sangen, Ryusho, Higashikawa, Toshihiro, Kiyosawa, Jun, Kanda, Tsugiyasu, Saito, Atsushi, Nakahashi, Takeshi, Ito, Tomohiko, Usuda, Daisuke, Okuro, Masashi, Hamada, Kazu, Maekawa, Naoto, Kasamaki, Yuji, Kuroki, Kengo, Iguchi, Masaharu, Fukuda, Akihiro, Ishigami, Keiichiro, Yamada, Shinya, Saito, Hitoshi, Mizuno, Takurou   +19 more
core   +1 more source

Tofogliflozin does not delay progression of carotid atherosclerosis in patients with type 2 diabetes: a prospective, randomized, open-label, parallel-group comparative study

Cardiovascular Diabetology, 2020
Background This study aimed to investigate the preventive effects of tofogliflozin, a selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, on atherosclerosis progression in type 2 diabetes (T2DM) patients without apparent cardiovascular disease ...
Naoto Katakami, Tomoya Mita, Hidenori Yoshii, Toshihiko Shiraiwa, Tetsuyuki Yasuda, Yosuke Okada, Keiichi Torimoto, Yutaka Umayahara, Hideaki Kaneto, Takeshi Osonoi, Tsunehiko Yamamoto, Nobuichi Kuribayashi, Kazuhisa Maeda, Hiroki Yokoyama, Keisuke Kosugi, Kentaro Ohtoshi, Isao Hayashi, Satoru Sumitani, Mamiko Tsugawa, Kayoko Ryomoto, Hideki Taki, Tadashi Nakamura, Satoshi Kawashima, Yasunori Sato, Hirotaka Watada, Iichiro Shimomura, the UTOPIA study investigators   +26 more
doaj   +1 more source

The Effect of Sodium-Dependent Glucose Cotransporter 2 Inhibitor Tofogliflozin on Neurovascular Coupling in the Retina in Type 2 Diabetic Mice

, 2022
We investigated the effect of tofogliflozin, a sodium-dependent glucose cotransporter 2 inhibitor (SGLT2i), on retinal blood flow dysregulation, neural retinal dysfunction, and the impaired neurovascular coupling in type 2 diabetic mice.
Akifumi Kushiyama, Sakura Kushiyama, Satoru Yamagami, Taiji Nagaoka, Masahisa Watanabe, Harumasa Yokota, Junya Hanaguri   +6 more
core   +1 more source

Frailty and low body mass index as key determinants of sodium-glucose cotransporter 2 inhibitor-specific adverse event-related discontinuation in adults aged ≥75 years: A multicenter real-world retrospective cohort study. [PDF]

J Diabetes Investig
Among Japanese adults aged ≥75 years newly initiating SGLT2 inhibitors, SGLT2 inhibitor–specific adverse event‐related discontinuation occurred in 9.1% within 180 days. Frailty and low BMI, rather than chronological age, were the key predictors, highlighting the importance of assessing physiological reserve before treatment initiation.
Uchida T, Ueno H, Konagata A, Nabekura H, Kikuchi Y, Beppu T, Sekishima A, Sekishima H, Nakamura T, Kogo F, Uehira Y, Tanaka Y, Yamaguchi H, Shimoda K.   +13 more
europepmc   +2 more sources

Therapeutic potential of tofogliflozin on nephrotic syndrome secondary to diabetic nephropathy [PDF]

Journal of Cardiology Cases, 2017
Diabetic nephropathy (DN) is a critical complication in patients with type 2 diabetes and regarded as a progressive disorder with a poor prognosis. The degree of albuminuria is associated closely with worse renal and cardiovascular outcomes. It is therefore important to achieve remission of proteinuria to avoid progression of DN and improve outcomes ...
Atsushi Tanaka, Tsukasa Nakamura, Eiichi Sato, Koichi Node   +3 more
openaire   +2 more sources

Changes in the eGFR in 102 patients treated over 12 months before the initiation of tofogliflozin administration.

, 2023
Changes in the eGFR in 102 patients treated over 12 months before the initiation of tofogliflozin administration.
Takuma Izutsu (10305465), Hideyuki Inoue (156340), Tomoko Yamasaki (1898185), Hiroyuki Ito (339050), Toshiko Mori (10305468), Suzuko Matsumoto (10305462), Michiko Togane (339061), Shinichi Antoku (339057)   +7 more
core   +1 more source

Safety and effectiveness of tofogliflozin in elderly Japanese patients with type 2 diabetes mellitus: A subanalysis of a post‐marketing study (J‐STEP/EL Study)

Journal of Diabetes Investigation, 2020
Aims/Introduction This subanalysis aimed to assess the safety and effectiveness of tofogliflozin by using data from the Japanese Study of Tofogliflozin with Type 2 Diabetes Mellitus Patients in an Observational Study of the Elderly to categorize elderly ...
Kohei Kaku, Yusuke Naito, Masayuki Senda, Yuji Kurihara, Ryoji Gunji, Seigo Kakiuchi, Kazunori Utsunomiya   +6 more
doaj   +1 more source

Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants with Type 2 Diabetes: A randomized, 48 -Weeks, Open-Label, Active-controlled Trial

, 2022
   OBJECTIVE Nonalcoholic fatty liver disease (NAFLD) is a liver phenotype of type 2 diabetes and obesity. Currently, the efficacy of sodium-glucose cotransporter 2 (SGLT2) inhibitors and sulfonylureas in liver pathology and hepatic gene expression ...
Yuki Kita (307050), Hiromasa Tsujiguchi, Yujiro Nakano (5003099), Eishiro Mizukoshi (292717), Hiromasa Tsujiguchi (4258522), Yujiro Nakano, Takeo Tanaka (7992962), Yumie Takeshita (307060), Yumie Takeshita, Kuniaki Arai (3398294), Toshinari Takamura (158655), Hisanori Goto (9198962), Tatsuya Yamashita, Hiroyuki Nakamura, Toshinari Takamura, Takeo Tanaka, Hiroyuki Nakamura (200082), Kenichi Harada (517436), Eishiro Mizukoshi, Shuichi Kaneko, Noriho Iida, Kuniaki Arai, Yuki Kita, Noriho Iida (8040884), Hisanori Goto, Masao Honda, Kenichi Harada, Noboru Takata (8255330), Tatsuya Yamashita (3067323), Shuichi Kaneko (156576), Noboru Takata, Masao Honda (156573)   +31 more
core   +1 more source